Chen Meilin, Chen Xiaomei, Chen Qinghong, Chu Chenyang, Yang Shuxuan, Wu Chuanghai, You Yanting, Hung Andrew, Yang Angela Wei Hong, Sun Xiaomin, Zhou Lin, Zhao Xiaoshan, Li Hong, Liu Yanyan
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
School of Science, STEM College, RMIT University, Melbourne, VIC, Australia.
Front Endocrinol (Lausanne). 2024 Dec 11;15:1436360. doi: 10.3389/fendo.2024.1436360. eCollection 2024.
Hyperuricemia (HUA) is a metabolic syndrome caused by purine metabolism disorders. (ZP) is a medicinal and food homologous plant, and its ripe peel is used to treat diseases and as a spice for cooking. Some studies have shown that ZP can inhibit the formation of xanthine oxidase and reduce the production of uric acid.
Through network pharmacology, ZP's potential targets and mechanisms for HUA treatment were identified. Databases like TCMSP, UniProt, and Swiss Target Prediction were utilized for ZP's active ingredients and targets. HUA-related targets were filtered using GeneCards, Drugbank, and Open Targets. Core targets for ZP's HUA treatment were mapped in a PPI network and analyzed with Cytoscape. GO and KEGG pathway enrichments were conducted on intersected targets via DAVID. Molecular docking and virtual screening were performed to find optimal binding pockets, and ADMET screening assessed compound safety. Molecular dynamics simulations confirmed compound stability in binding sites.
We identified 81 ZP active ingredient targets, 140 HUA-related targets, and 6 drug targets, with xanthine dehydrogenase (XDH) as the top core target. Molecular docking revealed ZP's active ingredients had strong binding to XDH. Virtual screening via Protein plus identified 48 compounds near the optimal binding pocket, with 2'-methylacetophenone, ledol, beta-sitosterol, and ethyl geranate as the most promising. Molecular dynamics simulations confirmed binding stability, suggesting ZP's potential in HUA prevention and the need for further experimental validation.
Our study provides foundations for exploring the mechanism of the lowering of uric acid by ZP and developing new products of ZP. The role of ZP in the diet may provide a new dietary strategy for the prevention of HUA, and more experimental studies are needed to confirm our results in the future.
高尿酸血症(HUA)是一种由嘌呤代谢紊乱引起的代谢综合征。(ZP)是一种药食同源植物,其成熟果皮用于治疗疾病和作为烹饪香料。一些研究表明,ZP可抑制黄嘌呤氧化酶的形成并减少尿酸的产生。
通过网络药理学确定ZP治疗HUA的潜在靶点和机制。利用中药系统药理学数据库(TCMSP)、通用蛋白质数据库(UniProt)和瑞士靶点预测数据库等数据库来确定ZP的活性成分和靶点。使用基因卡片数据库(GeneCards)、药物银行数据库(Drugbank)和开放靶点数据库(Open Targets)筛选与HUA相关的靶点。将ZP治疗HUA的核心靶点映射到蛋白质-蛋白质相互作用(PPI)网络中,并用Cytoscape软件进行分析。通过DAVID数据库对交集靶点进行基因本体(GO)和京都基因与基因组百科全书(KEGG)通路富集分析。进行分子对接和虚拟筛选以找到最佳结合口袋,并通过ADMET筛选评估化合物安全性。分子动力学模拟证实了化合物在结合位点的稳定性。
我们确定了81个ZP活性成分靶点、140个与HUA相关的靶点和6个药物靶点,其中黄嘌呤脱氢酶(XDH)是首要核心靶点。分子对接显示ZP的活性成分与XDH有很强的结合力。通过Protein plus进行虚拟筛选,在最佳结合口袋附近鉴定出48种化合物,其中2'-甲基苯乙酮、石竹烯、β-谷甾醇和香叶酸乙酯最具潜力。分子动力学模拟证实了结合稳定性,表明ZP在预防HUA方面具有潜力,但需要进一步的实验验证。
我们的研究为探索ZP降尿酸的机制和开发ZP新产品提供了基础。ZP在饮食中的作用可能为预防HUA提供一种新的饮食策略,未来需要更多的实验研究来证实我们的结果。